CAR-T Treatment in Myeloma: State of the Art

What does it take to design and lead a clinical trial in hematology? In this episode of EHA Unplugged, Prof. Elias K. Mai shares his experience transitioning from clinical practice to becoming a principal investigator, and how the EHA Clinical Research Training in Hematology (CRT ...  Show more

In this episode, Prof. Pieter Sonneveld is joined by Prof. Meletios Dimopoulos and Prof. Evangelos Terpos to discuss the updated EHA–EMN (European Myeloma Network) guidelines for the diagnosis, treatment and follow-up of multiple myeloma. The conversation explores how recent ther ...  Show more

Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ...  Show more

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provid ...  Show more

In this continuation of our myeloma series, we build on our prior discussion about myeloma pharmacology, this time discussing how to select the optimal regimen for treatment of our patients.

Co ...

Join the experts for an in-depth discussion on the latest developments in targeted therapies for relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and a look ahead to the upcoming EHA2024 conference. Credit available for this activity expires: 6/6/2025 Earn Credit / Lea ...  Show more